PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for...
15-Aug-2018 10:05 AM EDT Add to Favorites
MD Anderson and Accelerator Life Science Partners Launch Magnolia Neurosciences to Speed Development of Neuroprotective Therapies
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, today announced the launch of Magnolia Neurosciences Corporation, a company developing a new class of...
13-Aug-2018 6:00 AM EDT Add to Favorites
MD Anderson and Jazz Pharmaceuticals collaborate to evaluate potential treatment options for hematologic malignancies
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and...
6-Aug-2018 9:00 AM EDT Add to Favorites
Comprehensive CAR T-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators network
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and...
6-Aug-2018 8:05 AM EDT Add to Favorites
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone...
1-Aug-2018 9:40 AM EDT Add to Favorites
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team...
11-Jul-2018 11:05 AM EDT Add to Favorites
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to...
18-Jun-2018 11:00 PM EDT Add to Favorites
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called...
15-Jun-2018 10:00 AM EDT Add to Favorites
see all news
Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT
Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT
MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT
Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST
30-Oct-2013 8:10 PM EDT
30-Oct-2013 8:00 PM EDTsee all experts